Drug Topics March 1, 2024
Pfizer’s RSV vaccine received FDA approval on May 31, 2023.
Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo remains efficacious in preventing RSV-associated lower respiratory tract disease in adults aged 60 years and older through 2 full RSV seasons, according to topline study data shared by the manufacturer.1
Data were gathered as part of the ongoing phase 3 RENIOR clinical trial (NCT05035212).
“We are encouraged by the level of protection that we observed after 2 full RSV seasons for Abrysvo,” said Annaliesa Anderson, PhD, senior vice president and chief scientific officer, vaccine research and development at Pfizer, in a press release.1 “This new data indicate that broad and durable protection against both types of RSV that cause disease…is the potential benefit...
Today's Sponsors
Today's Sponsor